Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alpelisib

FDA-approved product (tablet, oral), marketed as Piqray, Vijoice.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alpelisib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phosphatidylinositol-3-kinase (pi3k) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alpelisib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alpelisib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

    NCT01719380 · start 2012-11-23

    Registered record
    Registry ID
    NCT01719380
    Conditions
    Colorectal Cancer
    Interventions
    LGX818; Cetuximab; BYL719
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-11-23
    Completion
    2019-02-12
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionLGX818; Cetuximab; BYL719
    PhasePhase 2
    Registry statusCompleted

  • A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

    NCT01449058 · start 2012-03

    Registered record
    Registry ID
    NCT01449058
    Conditions
    Advanced and Selected Solid Tumors; AML; High Risk and Very High Risk MDS
    Interventions
    BYL719; MEK162
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-03
    Completion
    2017-08-15
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced and Selected Solid Tumors; AML; High Risk and Very High Risk MDS
    InterventionBYL719; MEK162
    PhasePhase 1
    Registry statusCompleted

  • A Study of BYL719 in Adult Patients With Advanced Solid Malignancies

    NCT01387321 · start 2011-09-22

    Registered record
    Registry ID
    NCT01387321
    Conditions
    Advanced Solid Tumor
    Interventions
    BYL719
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09-22
    Completion
    2015-11-25
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionBYL719
    PhasePhase 1
    Registry statusCompleted

  • Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

    NCT01300962 · start 2011-08

    Registered record
    Registry ID
    NCT01300962
    Conditions
    Metastatic Breast Cancer
    Interventions
    BMK120; Capecitabine; BYL719; Trastuzumab; Lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2018-12-31
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionBMK120; Capecitabine; BYL719; Trastuzumab +1 more
    PhasePhase 1
    Registry statusCompleted

  • Compassionate Use of BYL 719 Alpelisib

    NCT03941782

    Registered record
    Registry ID
    NCT03941782
    Conditions
    Lymphangioma
    Interventions
    Alpelisib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioma
    InterventionAlpelisib
    PhaseNot recorded
    Registry statusNo longer available